Direct medical costs attributable to type 2 diabetes mellitus : a population-based study in Catalonia, Spain
Mata Cases, Manel (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Casajuana Closas, Marc (Universitat Autònoma de Barcelona)
Franch-Nadal, Josep (Institut Català de la Salut)
Casellas, Aina (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Castell, Conxa (Generalitat de Catalunya. Departament de Salut)
Vinagre Torres, Irene (Universitat de Barcelona)
Mauricio Puente, Dídac (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Bolíbar, Bonaventura (Universitat Autònoma de Barcelona)

Data:	2016
Resum:	We estimated healthcare costs associated with patients with type 2 diabetes compared with non-diabetic subjects in a population-based primary care database through a retrospective analysis of economic impact during 2011, including 126,811 patients with type 2 diabetes in Catalonia, Spain. Total annual costs included primary care visits, hospitalizations, referrals, diagnostic tests, selfmonitoring test strips, medication, and dialysis. For each patient, one control matched for age, gender and managing physician was randomly selected from a population database. The annual average cost per patient was €3110. 1 and €1803. 6 for diabetic and non-diabetic subjects, respectively (difference €1306. 6; i. e. , 72. 4 % increased cost). The costs of hospitalizations were €1303. 1 and €801. 6 (62. 0 % increase), and medication costs were €925. 0 and €489. 2 (89. 1 % increase) in diabetic and non-diabetic subjects, respectively. In type 2 diabetic patients, hospitalizations and medications had the greatest impact on the overall cost (41. 9 and 29. 7 %, respectively), generating approximately 70 % of the difference between diabetic and non-diabetic subjects. Patients with poor glycaemic control (glycated haemoglobin [7 %; [53 mmol/mol) had average costs of €3296. 5 versus €2848. 5 for patients with good control. In the absence of macrovascular complications, average costs were €3008. 1 for diabetic and €1612. 4 for non-diabetic subjects, while its presence increased costs to €4814. 6 and €3306. 8, respectively. In conclusion, the estimated higher costs for type 2 diabetes patients compared with non-diabetic subjects are due mainly to hospitalizations and medications, and are higher among diabetic patients with poor glycaemic control and macrovascular complications.
Ajuts:	Instituto de Salud Carlos III RD06/0018
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Type 2 diabetes ; Costs ; Primary care ; Retrospective ; Population database ; Catalonia ; Spain ; I1 ; H75
Publicat a:	The European Journal of Health Economics, Vol. 17, Issue 8 (November 2016) , p. 1001-1010, ISSN 1618-7601

DOI: 10.1007/s10198-015-0742-5
PMID: 26542160

10 p, 440.1 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats